Search results
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Kyowa Kirin is an R&D-based life sciences company with special strengths in biotechnology. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
Through a robust pipeline of promising drug candidates, pharmaceutical innovator Kyowa Kirin aims to ensure people around the world have access to safe, effective treatment. This page describes the company's research, technologies, and development schedules.
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue.
May 31, 2024 · This is the Kirin Holdings Kyowa Kirin page under the Pharmaceuticals domain page. It includes the specific business activities and product brands in the three main domains of the Kirin Group (Food & Beverages, Health Science and Pharmaceuticals).
Kyowa Kirin International develops and commercializes innovative prescription medicines for unmet medical needs. Explore our portfolio and commitment to improving patient lives.
May 14, 2024 · With over 500 people focused on this purpose we've become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of unmet therapeutic needs. Kyowa Kirin International plc is owned by Kyowa Kirin Co., Ltd. of Japan.
Kyowa Kirin International plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs.
Jan 24, 2024 · Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of Libmeldy® (atidarsagene autotemcel) in early-onset MLD.
Kyowa Kirin pursues scientific breakthroughs to address unmet clinical needs. Learn more about our portfolio of specialty medicines in nephrology, oncology, immunology & allergy, and neurology. Join us to grow your career or partner with us to propel your research discoveries into the hands of patients and physicians.
